Max Robotics — Global Service Robot Directory + US Certification

About

Dr. Annikka Weissferdt is a leading thoracic pathologist whose research has fundamentally advanced the understanding and treatment of non–small cell lung cancer (NSCLC). Her work centers on the intersection of immunotherapy, surgical pathology, and clinical outcomes, particularly in the neoadjuvant setting. Dr. Weissferdt’s major contributions include landmark studies evaluating the pathological response and surgical outcomes following novel immunotherapy combinations. Her most cited work, a 2022 study on neoadjuvant nivolumab alone or with ipilimumab (94 citations), demonstrated the feasibility and safety of these regimens, providing critical evidence for integrating immunotherapy before surgery. She further expanded this research in 2023, analyzing outcomes after chemotherapy combined with nivolumab and ipilimumab (19 citations), offering deeper insights into optimizing multimodal treatment. Through her detailed pathological assessments of resected specimens, Dr. Weissferdt has helped define key biomarkers of response, directly influencing clinical decision-making. Her work is essential for researchers and clinicians aiming to improve survival and surgical outcomes in NSCLC, establishing her as a pivotal figure in thoracic oncology and precision pathology.